Therapeutic Delivery of Tumor Suppressor miRNAs for Breast Cancer Treatment

被引:20
|
作者
Shinde, Sonali S. [1 ]
Ahmed, Sakeel [2 ]
Malik, Jonaid Ahmad [3 ,4 ]
Hani, Umme [5 ]
Khanam, Afreen [6 ]
Bhat, Faisal Ashraf [7 ]
Mir, Suhail Ahmad [8 ]
Ghazwani, Mohammed [5 ]
Wahab, Shadma [9 ]
Haider, Nazima [10 ]
Almehizia, Abdulrahman A. [11 ]
机构
[1] Dr Babasaheb Ambedkar Marathwada Univ, Dept Chem Technol, Aurangabad 431004, India
[2] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Ahmadabad 382355, India
[3] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Gauhati 781101, India
[4] Indian Inst Technol, Dept Biomed Engn, Rupnagar 140001, India
[5] King Khalid Univ, Coll Pharm, Dept Pharmaceut, Abha 62529, Saudi Arabia
[6] Jamia Hamdard, Dept Pharmacognosy & Phytochemistry, New Delhi 110062, India
[7] Jamia Hamdard, Dept Pharmacol, New Delhi 110062, India
[8] Univ Kashmir, Dept Pharmaceut Sci, Hazratbal, Srinagar 190006, Jammu & Kashmir, India
[9] King Khalid Univ, Coll Pharm, Dept Pharmacognosy, Abha 62529, Saudi Arabia
[10] King Khalid Univ, Coll Med, Dept Pathol, Abha 62529, Saudi Arabia
[11] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, Riyadh 11451, Saudi Arabia
来源
BIOLOGY-BASEL | 2023年 / 12卷 / 03期
关键词
breast cancer; miRNAs; multiple drug resistance; nanotechnology; MESOPOROUS SILICA NANOPARTICLES; MEDIATED CO-DELIVERY; RESISTANCE; EXPRESSION; MICRORNAS; DOXORUBICIN; METASTASIS; TARGET; CELLS; SIRNA;
D O I
10.3390/biology12030467
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Simple Summary The most frequent cancer in women is breast cancer (BC), which presents a significant risk to their good health. Over the past few decades, several factors have significantly affected BC progression and treatment. Additionally, microRNAs (miRNAs) that govern several oncogenes and tumor suppressors significantly control the expression networks during BC progression. As a result, miRNA-based therapies that changes these networks may modify the cellular activity to the point where they can treat BC. However, the most substantial challenges in developing such miRNA therapies are the stability and efficacy of their delivery systems. A comprehensive update describing various tumor suppressor miRNAs (TS miRNAs) in BC and their various delivery systems are discussed in this review. The death rate from breast cancer (BC) has dropped due to early detection and sophisticated therapeutic options, yet drug resistance and relapse remain barriers to effective, systematic treatment. Multiple mechanisms underlying miRNAs appear crucial in practically every aspect of cancer progression, including carcinogenesis, metastasis, and drug resistance, as evidenced by the elucidation of drug resistance. Non-coding RNAs called microRNAs (miRNAs) attach to complementary messenger RNAs and degrade them to inhibit the expression and translation to proteins. Evidence suggests that miRNAs play a vital role in developing numerous diseases, including cancer. They affect genes critical for cellular differentiation, proliferation, apoptosis, and metabolism. Recently studies have demonstrated that miRNAs serve as valuable biomarkers for BC. The contrast in the expression of miRNAs in normal tissue cells and tumors suggest that miRNAs are involved in breast cancer. The important aspect behind cancer etiology is the deregulation of miRNAs that can specifically influence cellular physiology. The main objective of this review is to emphasize the role and therapeutic capacity of tumor suppressor miRNAs in BC and the advancement in the delivery system that can deliver miRNAs specifically to cancerous cells. Various approaches are used to deliver these miRNAs to the cancer cells with the help of carrier molecules, like nanoparticles, poly D, L-lactic-co-glycolic acid (PLGA) particles, PEI polymers, modified extracellular vesicles, dendrimers, and liposomes. Additionally, we discuss advanced strategies of TS miRNA delivery techniques such as viral delivery, self-assembled RNA-triple-helix hydrogel drug delivery systems, and hyaluronic acid/protamine sulfate inter-polyelectrolyte complexes. Subsequently, we discuss challenges and prospects on TS miRNA therapeutic delivery in BC management so that miRNAs will become a routine technique in developing individualized patient profiles.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Development of therapeutic approaches based on the tumor suppressor microRNA-27b for breast cancer patients
    Takahashi, Ryou-u
    Ochiya, Takahiro
    Takemoto, Hiroyasu
    Nishiyama, Nobuhiro
    CANCER SCIENCE, 2018, 109 : 356 - 356
  • [22] Breast Cancer Stem Cells and Tumor Suppressor Genes
    Hwang-Verslues, Wendy W.
    Chang, King-Jen
    Lee, Eva Y-H. P.
    Lee, Wen-Hwa
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2008, 107 (10) : 751 - 766
  • [23] ZBTB7A is a tumor suppressor and novel therapeutic target in triple-negative breast cancer
    Molloy, Mary Ellen
    Lewinska, Monika
    Liu, Xue-Song
    Wang, Angela A.
    Yuan, Zhi-Min
    CANCER RESEARCH, 2016, 76
  • [24] Testin is a tumor suppressor and prognostic marker in breast cancer
    Zhu, Jiang
    Li, Xiaoyan
    Kong, Xiangnan
    Moran, Meena S.
    Su, Peng
    Haffty, Bruce G.
    Yang, Qifeng
    CANCER SCIENCE, 2012, 103 (12): : 2092 - 2101
  • [25] AMP≥2 Is a Putative Tumor Suppressor in Breast Cancer
    Fox, M. M.
    Phoenix, K. N.
    Claffey, K. R.
    CANCER RESEARCH, 2010, 70
  • [26] VWCE Functions as a Tumor Suppressor in Breast Cancer Cells
    Zhang, Dan
    Wan, Lili
    Yang, Fan
    Liu, Wenlan
    Liu, Litao
    He, Shengnan
    Xie, Ni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [27] Targeting tumor suppressor gene for breast cancer therapy
    Zhang, Ming
    Mahajan, Nitin
    Shi, Heidi Y.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 : S14 - S14
  • [29] CHIP ubiquitin ligase, tumor suppressor in breast cancer?
    Darbon, Jean-Marie
    BULLETIN DU CANCER, 2009, 96 (06) : 643 - 644
  • [30] miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review
    Vo, Thanh Hoa
    Abdelaal, Esam EL-Sherbieny
    Jordan, Emmet
    O'Donovan, Orla
    Mcneela, Edel A.
    Mehta, Jai Prakash
    Rani, Sweta
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2024, 37